Kane Biotech Inc (KNE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kane Biotech Inc (KNE) has a cash flow conversion efficiency ratio of 0.912x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-680.61K ≈ $-492.35K USD) by net assets (CA$-746.54K ≈ $-540.04K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Kane Biotech Inc for the company's overall valuation and market capitalisation.
Kane Biotech Inc - Cash Flow Conversion Efficiency Trend (2003–2025)
This chart illustrates how Kane Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kane Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kane Biotech Inc ranked by their cash flow conversion efficiency. Explore Kane Biotech Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Euroespes S.A.
MC:EEP
|
0.003x |
|
Chrysalis Investments Ltd
LSE:CHRY
|
-0.008x |
|
Osia Hyper Retail Limited
NSE:OSIAHYPER
|
-0.012x |
|
Madoro Metals Corp
V:MDM
|
-0.030x |
|
Soco Corporation Ltd
AU:SOC
|
-0.288x |
|
Biotron Ltd
AU:BIT
|
-0.322x |
|
International Lithium Corp
V:ILC
|
-0.028x |
|
Inix Technologies Holdings Bhd
KLSE:0094
|
0.015x |
Annual Cash Flow Conversion Efficiency for Kane Biotech Inc (2003–2025)
The table below shows the annual cash flow conversion efficiency of Kane Biotech Inc from 2003 to 2025. View KNE stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CA$-746.54K ≈ $-540.04K |
CA$-3.26 Million ≈ $-2.35 Million |
4.361x | +72.80% |
| 2024-12-31 | CA$-1.63 Million ≈ $-1.18 Million |
CA$-4.11 Million ≈ $-2.97 Million |
2.523x | +919.19% |
| 2023-12-31 | CA$-8.41 Million ≈ $-6.08 Million |
CA$-2.08 Million ≈ $-1.51 Million |
0.248x | -66.34% |
| 2022-12-31 | CA$-4.14 Million ≈ $-2.99 Million |
CA$-3.04 Million ≈ $-2.20 Million |
0.736x | -49.65% |
| 2021-12-31 | CA$-1.57 Million ≈ $-1.13 Million |
CA$-2.29 Million ≈ $-1.66 Million |
1.461x | +139.86% |
| 2020-12-31 | CA$1.07 Million ≈ $777.45K |
CA$-3.94 Million ≈ $-2.85 Million |
-3.665x | -221.02% |
| 2019-12-31 | CA$836.81K ≈ $605.33K |
CA$-955.37K ≈ $-691.10K |
-1.142x | -139.40% |
| 2018-12-31 | CA$-984.84K ≈ $-712.42K |
CA$-2.85 Million ≈ $-2.06 Million |
2.898x | +488.15% |
| 2017-12-31 | CA$2.74 Million ≈ $1.98 Million |
CA$-2.04 Million ≈ $-1.48 Million |
-0.747x | +57.43% |
| 2016-12-31 | CA$1.35 Million ≈ $974.76K |
CA$-2.36 Million ≈ $-1.71 Million |
-1.754x | +39.34% |
| 2015-12-31 | CA$480.25K ≈ $347.40K |
CA$-1.39 Million ≈ $-1.00 Million |
-2.891x | -265.11% |
| 2014-12-31 | CA$1.32 Million ≈ $958.43K |
CA$-1.05 Million ≈ $-758.95K |
-0.792x | +12.89% |
| 2013-12-31 | CA$1.28 Million ≈ $928.25K |
CA$-1.17 Million ≈ $-843.79K |
-0.909x | -84.75% |
| 2012-12-31 | CA$2.35 Million ≈ $1.70 Million |
CA$-1.16 Million ≈ $-835.72K |
-0.492x | -24.43% |
| 2011-12-31 | CA$2.38 Million ≈ $1.72 Million |
CA$-940.30K ≈ $-680.20K |
-0.395x | +41.91% |
| 2010-12-31 | CA$1.16 Million ≈ $841.74K |
CA$-792.06K ≈ $-572.96K |
-0.681x | -60.08% |
| 2009-12-31 | CA$1.80 Million ≈ $1.30 Million |
CA$-764.26K ≈ $-552.85K |
-0.425x | +40.87% |
| 2008-12-31 | CA$1.49 Million ≈ $1.08 Million |
CA$-1.07 Million ≈ $-776.48K |
-0.719x | -2.74% |
| 2007-12-31 | CA$1.14 Million ≈ $825.19K |
CA$-798.38K ≈ $-577.53K |
-0.700x | -18.27% |
| 2006-12-31 | CA$1.42 Million ≈ $1.03 Million |
CA$-843.13K ≈ $-609.91K |
-0.592x | +25.57% |
| 2005-12-31 | CA$1.02 Million ≈ $735.99K |
CA$-808.87K ≈ $-585.12K |
-0.795x | +32.63% |
| 2004-12-31 | CA$426.65K ≈ $308.63K |
CA$-503.50K ≈ $-364.22K |
-1.180x | -178.44% |
| 2003-12-31 | CA$955.27K ≈ $691.03K |
CA$-404.87K ≈ $-292.88K |
-0.424x | -- |
About Kane Biotech Inc
Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, a biofilm destabilizing formula with continuous activity; and DispersinB technology, a naturally occurring enzyme that cleaves the … Read more